UBS Group’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.52K Buy
443
+47
+12% +$1.03K ﹤0.01% 8668
2026
Q1
$7.94K Hold
396
﹤0.01% 8538
2025
Q4
$9.27K Sell
396
-116
-23% -$2.88K ﹤0.01% 8301
2025
Q3
$8.76K Sell
512
-481
-48% -$6.19K ﹤0.01% 8641
2025
Q2
$7.94K Sell
993
-1,388
-58% -$11.6K ﹤0.01% 8986
2025
Q1
$21.4K Sell
2,381
-100
-4% -$1.09K ﹤0.01% 8189
2024
Q4
$35.4K Buy
+2,481
New +$26.8K ﹤0.01% 7511
2023
Q4
Sell
-38
Closed -$72 9699
2023
Q3
$72 Buy
+38
New +$74 ﹤0.01% 8945
2023
Q1
Sell
-1,076
Closed -$936 10086
2022
Q4
$936 Buy
+1,076
New +$886 ﹤0.01% 10025

Other funds holding NAMSW

UBS Group's NAMSW Position: Q2 2026 in Review

UBS Group increased its NewAmsterdam Pharma Warrant (NAMSW) stake by 12% in Q2 2026, buying an estimated $1.03K and bringing the position to 443 shares worth $8.52K. The position accounts for ﹤0.01% of the portfolio, ranked #8668.

UBS Group first reported a position in NAMSW in Q4 2022 and has held it in 9 quarters since. The position peaked at $35.4K in Q4 2024. 9 funds tracked by Wall St. Rank hold NAMSW as of Q2 2026.

  • UBS Group held 443 shares of NewAmsterdam Pharma Warrant worth $8.52K as of Q2 2026.
  • UBS Group bought 47 NewAmsterdam Pharma Warrant shares in Q2 2026, an estimated $1.03K.
  • NewAmsterdam Pharma Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8668 holding.
  • UBS Group first reported a position in NewAmsterdam Pharma Warrant in Q4 2022 and has held it in 9 quarters since.
  • UBS Group's NewAmsterdam Pharma Warrant position peaked at $35.4K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.